Apitolisib

DB12180InvestigationalSmall molecule

Apitolisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Prostate Cancer, Renal Cell Carcinoma, and Endometrial Carcinoma, among others.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₂₃H₃₀N₈O₃S · 498.601 g/mol (avg)
Code names: G-038390 · G-038390.1 · GDC-0980 · GDC-0980.1 · GNE 390 · RG-7422

Resolves to

Compound

UNII1C854K1MIJCAS1032754-93-0ChEMBLCHEMBL1922094PubChem25254071

Structure

InChIKeyYOVVNQKCSKSHKT-HNNXBMFYSA-NSMILESC[C@H](O)C(=O)N1CCN(CC2=C(C)C3=NC(=NC(N4CCOCC4)=C3S2)C2=CN=C(N)N=C2)CC1

Targets

P42345MTORP48736PIK3CG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Apitolisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account